The MetNET-2 Trial
NCT02823691
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
Lanreotide and Metformin
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano